FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2542816102> ?p ?o ?g. }

• W2542816102 endingPage "A416" @default.
• W2542816102 startingPage "A416" @default.
• W2542816102 abstract "Treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin (OBV/PTV/r±DSV±R) achieved high sustained virologic response rates (SVR). We evaluated long-term clinical and economic outcomes of OBV/PTV/r±DSV±R compared with other antiviral treatments for treatment-naïve and -experienced chronic hepatitis C (CHC) patients infected with genotype-1 (GT1) or genotype-4 (GT4) in France. A Markov cohort simulation model for the French health care setting was developed and applied to evaluate the following antiviral treatment regimens: peginterferon+ribavirin (P+R), telaprevir+P+R (TVR+P+R), boceprevir+P+R (BOC+P+R), sofosbuvir+P+R (SOF+P+R), simeprevir+P+R (SIM+P+R), SOF+R, SOF+SIM, SOF+daclatasvir±R (SOF+DAC±R), SOF+ledipasvir±R (SOF+LDV±R), OBV/PTV/r±DSV±R. Disease progression rates were abstracted from international literature. Treatment regimens were based on European and French treatment guidelines. Treatment related changes in quality-of-life (QoL), SVR, and adverse events were based on international clinical trial data. We used French data on population characteristics, disease-related QoL, and costs (index year 2014/15) from published literature, databases and original studies. Analyses were conducted from the collective payer’s perspective with 4% annual discount rate for costs and effects and a lifelong time horizon. Outcomes included lifetime costs, life years (LY), quality-adjusted life years (QALY), and the incremental cost-effectiveness ratio (ICER). Comprehensive sensitivity analyses were performed. Compared to no antiviral therapy, OBV/PTV/r±DSV±R gained 1.1-1.6 LYs (1.6-2.0 QALYs) depending on treatment history and genotype. OBV/PTV/r±DSV±R achieved ICERs of 30,089 Euro/QALY (vs. SIM+P+R) in GT1 and 30,422 Euro/QALY (vs. SIM+P+R) in GT4 treatment-naïve patients. The corresponding ICERs in treatment-experienced patients were 18,790 Euro/QALY in GT1 (vs. SIM+P+R) and 9,479 Euro/QALY in GT4 (vs. no treatment). Parameters with the greatest influence on the ICER in deterministic sensitivity analyses were the SVR, discount rate, progression to advanced disease and the relative utility for being HCV-RNA positive. Based on our analyses, antiviral treatment with OBV/PTV/r±DSV±R prolongs life and can be considered cost-effective in treatment-naïve and -experienced CHC patients infected with genotype-1 or genotype-4." @default.
• W2542816102 created "2016-11-04" @default.
• W2542816102 creator A5007269697 @default.
• W2542816102 creator A5012881850 @default.
• W2542816102 creator A5034696787 @default.
• W2542816102 creator A5040975493 @default.
• W2542816102 creator A5045695532 @default.
• W2542816102 creator A5057090494 @default.
• W2542816102 creator A5065617907 @default.
• W2542816102 creator A5068111122 @default.
• W2542816102 date "2016-11-01" @default.
• W2542816102 modified "2023-09-27" @default.
• W2542816102 title "Cost-Effectiveness Of Ombitasvir/Paritaprevir/Ritonavir With Or Without Dasabuvir For The Treatment Of Chronic Hepatitis C Patients Infected With Genotype 1 Or 4 In France" @default.
• W2542816102 doi "https://doi.org/10.1016/j.jval.2016.09.404" @default.
• W2542816102 hasPublicationYear "2016" @default.
• W2542816102 type Work @default.
• W2542816102 sameAs 2542816102 @default.
• W2542816102 citedByCount "0" @default.
• W2542816102 crossrefType "journal-article" @default.
• W2542816102 hasAuthorship W2542816102A5007269697 @default.
• W2542816102 hasAuthorship W2542816102A5012881850 @default.
• W2542816102 hasAuthorship W2542816102A5034696787 @default.
• W2542816102 hasAuthorship W2542816102A5040975493 @default.
• W2542816102 hasAuthorship W2542816102A5045695532 @default.
• W2542816102 hasAuthorship W2542816102A5057090494 @default.
• W2542816102 hasAuthorship W2542816102A5065617907 @default.
• W2542816102 hasAuthorship W2542816102A5068111122 @default.
• W2542816102 hasBestOaLocation W25428161021 @default.
• W2542816102 hasConcept C126322002 @default.
• W2542816102 hasConcept C142462285 @default.
• W2542816102 hasConcept C159047783 @default.
• W2542816102 hasConcept C2522874641 @default.
• W2542816102 hasConcept C2775999097 @default.
• W2542816102 hasConcept C2776408679 @default.
• W2542816102 hasConcept C2776455275 @default.
• W2542816102 hasConcept C2777100407 @default.
• W2542816102 hasConcept C2777159539 @default.
• W2542816102 hasConcept C2778159067 @default.
• W2542816102 hasConcept C2778390639 @default.
• W2542816102 hasConcept C2778785139 @default.
• W2542816102 hasConcept C2778867932 @default.
• W2542816102 hasConcept C2778986448 @default.
• W2542816102 hasConcept C2779298103 @default.
• W2542816102 hasConcept C2780040827 @default.
• W2542816102 hasConcept C2908647359 @default.
• W2542816102 hasConcept C2993143319 @default.
• W2542816102 hasConcept C71924100 @default.
• W2542816102 hasConcept C90924648 @default.
• W2542816102 hasConcept C99454951 @default.
• W2542816102 hasConceptScore W2542816102C126322002 @default.
• W2542816102 hasConceptScore W2542816102C142462285 @default.
• W2542816102 hasConceptScore W2542816102C159047783 @default.
• W2542816102 hasConceptScore W2542816102C2522874641 @default.
• W2542816102 hasConceptScore W2542816102C2775999097 @default.
• W2542816102 hasConceptScore W2542816102C2776408679 @default.
• W2542816102 hasConceptScore W2542816102C2776455275 @default.
• W2542816102 hasConceptScore W2542816102C2777100407 @default.
• W2542816102 hasConceptScore W2542816102C2777159539 @default.
• W2542816102 hasConceptScore W2542816102C2778159067 @default.
• W2542816102 hasConceptScore W2542816102C2778390639 @default.
• W2542816102 hasConceptScore W2542816102C2778785139 @default.
• W2542816102 hasConceptScore W2542816102C2778867932 @default.
• W2542816102 hasConceptScore W2542816102C2778986448 @default.
• W2542816102 hasConceptScore W2542816102C2779298103 @default.
• W2542816102 hasConceptScore W2542816102C2780040827 @default.
• W2542816102 hasConceptScore W2542816102C2908647359 @default.
• W2542816102 hasConceptScore W2542816102C2993143319 @default.
• W2542816102 hasConceptScore W2542816102C71924100 @default.
• W2542816102 hasConceptScore W2542816102C90924648 @default.
• W2542816102 hasConceptScore W2542816102C99454951 @default.
• W2542816102 hasIssue "7" @default.
• W2542816102 hasLocation W25428161021 @default.
• W2542816102 hasOpenAccess W2542816102 @default.
• W2542816102 hasPrimaryLocation W25428161021 @default.
• W2542816102 hasRelatedWork W1872176752 @default.
• W2542816102 hasRelatedWork W2014828596 @default.
• W2542816102 hasRelatedWork W2433875347 @default.
• W2542816102 hasRelatedWork W2482751952 @default.
• W2542816102 hasRelatedWork W2552228682 @default.
• W2542816102 hasRelatedWork W2608524881 @default.
• W2542816102 hasRelatedWork W2623529997 @default.
• W2542816102 hasRelatedWork W2945285279 @default.
• W2542816102 hasRelatedWork W3158266937 @default.
• W2542816102 hasRelatedWork W3160703242 @default.
• W2542816102 hasVolume "19" @default.
• W2542816102 isParatext "false" @default.
• W2542816102 isRetracted "false" @default.
• W2542816102 magId "2542816102" @default.
• W2542816102 workType "article" @default.